Sagimet Q2 net loss $10.4M, cash $135.5M; denifanstat meets all acne Phase 3 endpoints

Sagimet Biosciences Inc.

2025-Q2 EPS reported -$0.89 vs consensus -$0.52 ▼ miss (-71.9%)

Net loss Q2 2025 $10.4M vs $8.1M; H1 loss $28.6M vs $14.7M; R&D and G&A both increased.
Cash position $135.5M at June 30, 2025; no revenue reported (pre-revenue biotech).
Denifanstat Phase 3 acne trial (Ascletis) met all endpoints: treatment success 33.2% vs 14.6% (p<0.0001).
Initiated Phase 1 for TVB-3567 (acne) in U.S.; combo trial denifanstat+resmetirom PK study planned 2H 2025 with readout 1H 2026.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.